Welcome to our dedicated page for Chemours Co SEC filings (Ticker: CC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking how Chemours manages titanium dioxide pricing cycles, PFAS litigation reserves, or refrigerant phase-down costs can feel like wading through hundreds of pages of SEC text. Our platform tackles that complexity head-on. The moment a Chemours 8-K material events explained notice or Chemours insider trading Form 4 transactions hits EDGAR, Stock Titan’s AI parses it, flags the environmental, legal, and segment earnings details investors hunt for, and delivers a clear summary you can read in minutes.
Need the latest Chemours quarterly earnings report 10-Q filing? We link the PDF, highlight Ti-Pure™ pricing disclosures, and translate footnotes into plain English. Curious about executive moves? Real-time alerts on Chemours Form 4 insider transactions real-time show exactly when directors buy or sell—critical context before pigment price announcements. Our coverage spans every form: the annual report—Chemours annual report 10-K simplified—with AI-driven red-line comparisons, the proxy statement outlining Chemours proxy statement executive compensation, down to niche S-3 shelf registrations.
Professionals use these insights to: 1) monitor litigation accrual swings quarter-to-quarter, 2) compare segment EBITDA trends without digging through exhibits, 3) follow Chemours executive stock transactions Form 4 ahead of earnings. Whether you ask “understanding Chemours SEC documents with AI” or search “Chemours earnings report filing analysis,” this page delivers concise answers, complete filings, and expert context—all continuously updated so you never miss a disclosure that moves the stock.
The Form 4 filing reports that Chemours Company (CC) director Courtney Mather was awarded 2,292 deferred stock units (DSUs) on 30 June 2025. Each DSU equals one share of common stock and will be settled in the first month after the director leaves the board. The award is recorded at a reference price of $11.45 per unit. After the grant, Mather directly owns 2,292 derivative securities; no sales or additional purchases of common stock were disclosed. Apart from this routine director compensation grant, the filing contains no other material transactions or changes in ownership.
Dillard’s, Inc. (DDS) Form 4 filing dated 07/02/2025 discloses a modest open-market purchase by long-time insider Drue Matheny, Executive Vice President and Director. On 06/30/2025 Matheny acquired 19 Class A common shares at $413.32 each, increasing her direct holding to 403,904 shares. She also continues to hold 36,648 shares through the company retirement plan and 9,821 shares indirectly (7,300 as trustee of the GST Trust and 2,521 held by her spouse). No derivative transactions were reported.
The purchase represents less than 0.005% of her direct ownership and is immaterial to DDS’s 17 million share float, yet any insider buying—particularly by a senior executive—may be interpreted as a confidence signal. There were no sales, option exercises, or 10b5-1 plan indications, and the filing confirms her continuing status as both officer and director.
FAQ
What is the current stock price of Chemours Co (CC)?
What is the market cap of Chemours Co (CC)?
What are the core business segments of Chemours Co?
How did Chemours Co originate?
What role does titanium dioxide play in Chemours' product portfolio?
How does Chemours address energy efficiency in its products?
In what way does Chemours contribute to the development of electric vehicles?
How does Chemours maintain its position in a competitive market?
Can you summarize the impact of Chemours' research and innovation?
